跳转至内容
Merck
CN

S9509

Supelco

(±)-磺吡酮

analytical standard

别名:

1,2-二苯基-4-(苯亚砜基乙基)-3,5-吡咯烷二酮, 二苯基吡嗪酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H20N2O3S
CAS号:
分子量:
404.48
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

analytical standard

质量水平

方案

≥99%

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

cleaning products
cosmetics
food and beverages
forensics and toxicology
personal care
pharmaceutical (small molecule)
veterinary

包装形式

neat

SMILES字符串

O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4

InChI

1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

InChI key

MBGGBVCUIVRRBF-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

磺吡酮是一种1,3-二羰基尿酸尿酸药物,可用于治疗与痛风有关的高尿酸血症。

应用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9 (UGT1A9)
Kerdpin O, et al.
Drug Metabolism and Disposition, 50(1), 26-36 (2006)
Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Lin L, et al.
Journal of functional foods, 50(1), 26-36 (2018)
High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites
Holcapek M, et al.
Analytical and Bioanalytical Chemistry, 391(1), 59-78 (2008)
D H Solomon et al.
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
Sharon L Ripp et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(10), 1742-1748 (2006-07-14)
Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in decreased exposure to coadministered drugs, with potential loss of efficacy. Immortalized hepatocytes (Fa2N-4 cells) have been proposed as

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门